Deborah R Taylor

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets
    Miriam E R Darnell
    Laboratory of Hepatitis and Related Emerging Agents, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, CBER FDA, Bethesda, MD 20892, USA
    J Infect Dis 196:1329-38. 2007
  2. ncbi Obstacles and advances in SARS vaccine development
    Deborah R Taylor
    Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, Center for Biologics Evaluation and Research CBER, US Food and Drug Administration, Bethesda, MD 20892, USA
    Vaccine 24:863-71. 2006
  3. ncbi New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1
    Deborah R Taylor
    CBER FDA, HFM 448, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol 79:6291-8. 2005
  4. ncbi Persistent growth of a human plasma-derived hepatitis C virus genotype 1b isolate in cell culture
    Erica Silberstein
    Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    PLoS Pathog 6:e1000910. 2010
  5. ncbi Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products
    Miriam E R Darnell
    Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Bethesda, Maryland, USA
    Transfusion 46:1770-7. 2006
  6. ncbi Achieving a golden mean: mechanisms by which coronaviruses ensure synthesis of the correct stoichiometric ratios of viral proteins
    Ewan P Plant
    Laboratory of Hepatitis and Related Emerging Agents, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, CBER, FDA, 8800 Rockville Pike, HFM310, Bethesda, Maryland 20892, USA
    J Virol 84:4330-40. 2010
  7. ncbi Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV
    Miriam E R Darnell
    Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448, Bethesda, MD 20892, USA
    J Virol Methods 121:85-91. 2004
  8. ncbi Innate immunity and hepatitis C virus: eluding the host cell defense
    Deborah R Taylor
    Laboratory of Hepatitis and Related Emerging Agents, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, CBER FDA, Bethesda, MD 20892, USA
    Front Biosci 14:4950-61. 2009
  9. ncbi Protein synthesis and endoplasmic reticulum stress can be modulated by the hepatitis C virus envelope protein E2 through the eukaryotic initiation factor 2alpha kinase PERK
    Nicole Pavio
    Howard Hughes Medical Institute, Department of Molecular Microbiology and Immunology, School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    J Virol 77:3578-85. 2003
  10. ncbi Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins
    Stephanie T Shi
    Department of Molecular Microbiology and Immunology, University of Southern California, Keck School of Medicine, Los Angeles, California 90033, USA
    Virology 292:198-210. 2002

Collaborators

Detail Information

Publications11

  1. ncbi Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets
    Miriam E R Darnell
    Laboratory of Hepatitis and Related Emerging Agents, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, CBER FDA, Bethesda, MD 20892, USA
    J Infect Dis 196:1329-38. 2007
    ..Previous vaccine reports have noted robust neutralizing antibody and inflammatory responses in ferrets, resulting in enhanced hepatitis...
  2. ncbi Obstacles and advances in SARS vaccine development
    Deborah R Taylor
    Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, Center for Biologics Evaluation and Research CBER, US Food and Drug Administration, Bethesda, MD 20892, USA
    Vaccine 24:863-71. 2006
    ..Described here are issues related to progress in vaccine development and the obstacles that lie ahead for both researchers and regulatory agencies...
  3. ncbi New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1
    Deborah R Taylor
    CBER FDA, HFM 448, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol 79:6291-8. 2005
    ..These results may explain successful HCV replicon clearance by IFN-alpha in vitro and may provide a promising new therapeutic strategy for HCV as well as other viral infections...
  4. ncbi Persistent growth of a human plasma-derived hepatitis C virus genotype 1b isolate in cell culture
    Erica Silberstein
    Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    PLoS Pathog 6:e1000910. 2010
    ..This virus constitutes a novel tool for the study of one of the most relevant strains of HCV, genotype 1b, which will now be available for HCV life cycle research and useful for the development of new therapeutics...
  5. ncbi Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products
    Miriam E R Darnell
    Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Bethesda, Maryland, USA
    Transfusion 46:1770-7. 2006
    ..CONCLUSION: Heat, UVC irradiation, and S/D treatments effectively inactivate SARS-CoV, whereas octanoic acid treatment is insufficient for inactivation of the virus...
  6. ncbi Achieving a golden mean: mechanisms by which coronaviruses ensure synthesis of the correct stoichiometric ratios of viral proteins
    Ewan P Plant
    Laboratory of Hepatitis and Related Emerging Agents, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, CBER, FDA, 8800 Rockville Pike, HFM310, Bethesda, Maryland 20892, USA
    J Virol 84:4330-40. 2010
    ..The findings of these analyses all support a "golden mean" model in which viruses use both programmed ribosomal frameshifting and translational attenuation to control the relative ratios of their encoded proteins...
  7. ncbi Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV
    Miriam E R Darnell
    Center for Biologics Evaluation and Research, US Food and Drug Administration, 8800 Rockville Pike, HFM448, Bethesda, MD 20892, USA
    J Virol Methods 121:85-91. 2004
    ..We describe the kinetics of these efficient viral inactivation methods, which will allow research with SARS-CoV containing materials, that are rendered non-infectious, to be conducted at reduced safety levels...
  8. ncbi Innate immunity and hepatitis C virus: eluding the host cell defense
    Deborah R Taylor
    Laboratory of Hepatitis and Related Emerging Agents, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, CBER FDA, Bethesda, MD 20892, USA
    Front Biosci 14:4950-61. 2009
    ..Here we review the different ways that HCV evades the immune response elicited by IFN...
  9. ncbi Protein synthesis and endoplasmic reticulum stress can be modulated by the hepatitis C virus envelope protein E2 through the eukaryotic initiation factor 2alpha kinase PERK
    Nicole Pavio
    Howard Hughes Medical Institute, Department of Molecular Microbiology and Immunology, School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    J Virol 77:3578-85. 2003
    ..These findings may also explain how the virus promotes persistent infection by overcoming the cellular ER stress response...
  10. ncbi Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins
    Stephanie T Shi
    Department of Molecular Microbiology and Immunology, University of Southern California, Keck School of Medicine, Los Angeles, California 90033, USA
    Virology 292:198-210. 2002
    ....
  11. ncbi Detection of a novel unglycosylated form of hepatitis C virus E2 envelope protein that is located in the cytosol and interacts with PKR
    Nicole Pavio
    Howard Hughes Medical Institute, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    J Virol 76:1265-72. 2002
    ..Thus, an ER protein can exist in the cytosol as an unglycosylated species and impair cellular functions...